Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma

BackgroundMany clinical studies have shown that patients with non-small cell lung carcinoma (NSCLC) can benefit from immune checkpoint inhibitor (ICI) therapy; however, PD-L1 and tumor mutation burden (TMB), which are recommended by the NCCN guidelines, are still insufficient in predicting the respo...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Liuning Li, Guojie Lu, Yang Liu, Longlong Gong, Xue Zheng, Hongbo Zheng, Weiguang Gu, Lin Yang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2021-06-01
Edice:	Frontiers in Oncology
Témata:	immune checkpoint inhibitor therapy non-small cell lung carcinoma T cells macrophages biomarker
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fonc.2021.658690/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!